{"id":44282,"date":"2024-10-07T13:33:00","date_gmt":"2024-10-07T11:33:00","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=44282"},"modified":"2024-10-24T13:33:42","modified_gmt":"2024-10-24T11:33:42","slug":"gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/","title":{"rendered":"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

In the past week, the Nordic biotech and healthcare stocks declined 2.8%. Curasight rose 24% following positive rights issue news, an insider bought shares in Saniona following a positive update on SAN2355, and Zealand Pharma, Genmab, and Gubra got new price targets with Gubra’s being 80% above the current share price. Finally, CS Medica fell 20% and has now been in a downward trend since the beginning of August. <\/strong><\/p>\n\n\n\n

6 of the 22 Danish biotech companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date.<\/strong> Obesity continues to drive the best performances with Gubra and Pila Pharma having strong YTD performance.<\/strong> Three <\/strong><\/span>Danish healthcare stocks with +100% YTD return.<\/strong><\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix AB<\/a><\/strong><\/p>\n\n\n\n

Acarix resolves on a directed issue to the guarantors of the warrant series 3 (Link<\/a>)<\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon\u2122 hGH for the Treatment of Adults with Growth Hormone Deficiency<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon\u2122 PTH (Palopegteriparatide) Presented at ASBMR 2024 (Link<\/a>)<\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/p>\n\n\n\n

CS Medica<\/a><\/strong><\/p>\n\n\n\n

CS MEDICA’s Subsidiary Signs Agreement to Target the German Market, Leveraging Expertise of Nimbus Health, a Dr. Reddy’s Laboratories company<\/em><\/em> (Link<\/a>)<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

CS MEDICA A\/S Secures Sales Approval in Azerbaijan & Georgia, Valued at 1.17 mDKK (Link<\/a>)<\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

Curasight A\/S rights issue heavily oversubscribed<\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

Recent clinical data confirms significantly improved predictive power of Evaxion’s AI-Immunology\u2122 platform (Link<\/a>)<\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

Svenska Handelsbanken lowered their price target from DKK 2,400 to DKK 2,250<\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

Kempen put a price target of DKK 870 on Gubra compared to its current share price of DKK 483<\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer\u2019s (SITC) 39th Annual Meeting<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

Saniona Provides Update on Major Progress for SAN2355<\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

A board member of Saniona bought shares for MSEK 0.5 at around 4.15-4.20 a share.<\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

Deutsche Bank put a price of DKK 815 on Zealand Pharma during the week<\/p>\n\n\n\n

Y-mAbs Therapeutic<\/a><\/strong><\/p>\n\n\n\n

Y-mAbs to Participate in Upcoming Investor Conferences in October<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Share price development – Danish stocks<\/strong><\/p>\n\n\n\n

On average, the Danish biotech and healthcare stocks delivered a negative return of 2.8%. Most notably, <\/strong><\/a>Curasight<\/a><\/strong><\/strong> rose 24% following positive news about their rights issue. Capital raising has been a challenge for Curasight in 2024, but the company now seems to be moving ahead successfully driving the share price higher. Further, a board member bought shares in Saniona<\/a><\/strong> after they gave a positive update on SAN2355. Additionally, Zealand Pharma<\/a><\/strong>, Genmab<\/a><\/strong>, and Gubra<\/a><\/strong> got new price targets with the latter getting the most positive one. On the other hand, CS Medica<\/a><\/strong> declined 20% although the company got sales approval in Azerbaijan & Georgia.<\/p>\n\n\n\n

Gubra<\/a><\/strong> continues to be the best-performing stock year-to-date with a return of 275%. Pila Pharma<\/a><\/strong>, Zealand Pharma<\/a><\/strong>, and Y-mAbs Therapeutic<\/a><\/strong> have also generated returns of over 100% in 2024. Cessatech<\/a><\/strong> currently stands at 96%.<\/p>\n\n\n\n

Investment case for Curasight<\/a><\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve month<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC)<\/strong> fell 0.4% to 66,85. The index has had a strong performance since the beginning of October last year and it has now not only surpassed the KPNGX index but it has also joined the larger indexes in terms of performance. In the past 12 months, the KPHC index has underperformed relative to large caps, while it has outperformed the broader Nordic growth exchanges by quite a lot.<\/p>\n\n\n\n

Price charts for the KPHC, KPNGX, C25, and S30 index for the past twelve months<\/strong><\/p>\n\n\n\n

\"\"
The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.<\/sup><\/figcaption><\/figure>\n\n\n\n

31-134% in weekly return for the Nordic healthcare stocks<\/strong><\/p>\n\n\n\n

Diagonal Bio AB<\/a> (134%)<\/strong> is developing a platform under the name Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service, and associated ancillary services are also offered. The company rose significantly from October 3rd to October 4th without any news. The stock even continued today with another 64% increase.<\/p>\n\n\n\n

Carbiotrix AB<\/a> (127%)<\/strong> is a biotechnology company in microbiome care through upcycled prebiotics. Carbiotix’s mission is to improve people’s health by increasing the consumption of prebiotics. Carbiotix today offers a core service called NutraCycle, an on-site upcycling and enrichment service that enables food and beverage, ingredient and feed manufacturers to transform plant-based products into functional products. <\/p>\n\n\n\n

Chordate Medical Holding AB<\/a> (31%)<\/strong>  is a medical technology company that has developed, patented and CE-marked a nerve-modulating treatment technique for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (KOS). The company sells its products to treating clinics in selected European markets, Israel, and Saudi Arabia, with the aim of increasing its presence in the global market. The stock rose following news of the announcement of its first order for Ozilia Migraine treatment from Saudi Arabia.<\/p>\n\n\n\n

Resources: Refinitiv Eikon, Cision, Nordnet & company websites<\/strong><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined 2.8%. Curasight rose 24% following positive rights issue news, an insider bought shares in Saniona following a positive update on SAN2355, and Zealand Pharma, Genmab, and Gubra got new […]<\/p>\n","protected":false},"author":11,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[29],"tags":[],"class_list":["post-44282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investeringscases"],"acf":[],"yoast_head":"\nGubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined 2.8%. Curasight rose 24% following positive rights issue news, an insider bought shares in Saniona following a positive update on SAN2355, and Zealand Pharma, Genmab, and Gubra got new […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-07T11:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T11:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week\",\"datePublished\":\"2024-10-07T11:33:00+00:00\",\"dateModified\":\"2024-10-24T11:33:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/\"},\"wordCount\":943,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"Investeringscases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/\",\"name\":\"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2024-10-07T11:33:00+00:00\",\"dateModified\":\"2024-10-24T11:33:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investeringscases\",\"item\":\"https:\/\/kapitalpartner.dk\/category\/investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/","og_locale":"en_US","og_type":"article","og_title":"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks declined 2.8%. Curasight rose 24% following positive rights issue news, an insider bought shares in Saniona following a positive update on SAN2355, and Zealand Pharma, Genmab, and Gubra got new […]","og_url":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2024-10-07T11:33:00+00:00","article_modified_time":"2024-10-24T11:33:42+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week","datePublished":"2024-10-07T11:33:00+00:00","dateModified":"2024-10-24T11:33:42+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/"},"wordCount":943,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["Investeringscases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/","url":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/","name":"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2024-10-07T11:33:00+00:00","dateModified":"2024-10-24T11:33:42+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/gubra-gets-very-high-price-target-and-curasight-with-positive-rights-issue-news-diagonal-bio-best-last-week\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investeringscases","item":"https:\/\/kapitalpartner.dk\/category\/investeringscases\/"},{"@type":"ListItem","position":3,"name":"Gubra gets very high price target and Curasight with positive rights issue news, Diagonal Bio best last week"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44282"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=44282"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44282\/revisions"}],"predecessor-version":[{"id":44283,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44282\/revisions\/44283"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=44282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=44282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=44282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}